Volition Expands Commercialization Push with rNuQ Nucleosome Webshop
Event summary
- Volition launched rNuQ webshop offering recombinant nucleosomes for research use on April 20, 2026
- Products manufactured in ISO 13485 certified facility, shipped at +4°C in glycerol-free buffer
- Nu.Q® Discover pillar serves 100+ clients including top pharma companies
- 2025 revenue growth for Nu.Q® Discover was 86%, with similar trajectory anticipated for 2026
The big picture
Volition's launch of the rNuQ webshop represents a strategic expansion of its commercialization efforts in the epigenetics space. The move comes as the company seeks to leverage its 10-year R&D investment in recombinant nucleosomes, positioning itself as a key supplier to pharmaceutical and diagnostic companies. With growing adoption of its Nu.Q® Discover platform and discussions for bespoke assay development, Volition is expanding its revenue streams while maintaining its focus on disease research and drug development.
What we're watching
- Revenue Diversification
- Whether Volition can sustain 86% revenue growth trajectory through new product lines
- Pharma Partnerships
- The pace at which Volition secures bespoke assay development deals with pharmaceutical companies
- Market Expansion
- How quickly Volition can penetrate new biospecimen markets beyond blood plasma
Related topics